<code id='AB5F787196'></code><style id='AB5F787196'></style>
    • <acronym id='AB5F787196'></acronym>
      <center id='AB5F787196'><center id='AB5F787196'><tfoot id='AB5F787196'></tfoot></center><abbr id='AB5F787196'><dir id='AB5F787196'><tfoot id='AB5F787196'></tfoot><noframes id='AB5F787196'>

    • <optgroup id='AB5F787196'><strike id='AB5F787196'><sup id='AB5F787196'></sup></strike><code id='AB5F787196'></code></optgroup>
        1. <b id='AB5F787196'><label id='AB5F787196'><select id='AB5F787196'><dt id='AB5F787196'><span id='AB5F787196'></span></dt></select></label></b><u id='AB5F787196'></u>
          <i id='AB5F787196'><strike id='AB5F787196'><tt id='AB5F787196'><pre id='AB5F787196'></pre></tt></strike></i>

          leisure time

          leisure time

          author:entertainment    Page View:4
          illustration of one blue dna strand
          Adobe

          The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

          Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

          advertisement

          Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more
          George Santos makes 1st court appearance after pleading not guilty to 13 counts
          George Santos makes 1st court appearance after pleading not guilty to 13 counts

          1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more

          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha